CA3232566A1 - Dried nanoparticle compositions - Google Patents
Dried nanoparticle compositions Download PDFInfo
- Publication number
- CA3232566A1 CA3232566A1 CA3232566A CA3232566A CA3232566A1 CA 3232566 A1 CA3232566 A1 CA 3232566A1 CA 3232566 A CA3232566 A CA 3232566A CA 3232566 A CA3232566 A CA 3232566A CA 3232566 A1 CA3232566 A1 CA 3232566A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- lipid carrier
- nucleic acid
- rna
- oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Optics & Photonics (AREA)
- General Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247172P | 2021-09-22 | 2021-09-22 | |
| US63/247,172 | 2021-09-22 | ||
| US202263297449P | 2022-01-07 | 2022-01-07 | |
| US63/297,449 | 2022-01-07 | ||
| PCT/US2022/013508 WO2023048758A1 (en) | 2021-09-22 | 2022-01-24 | Dried nanoparticle compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3232566A1 true CA3232566A1 (en) | 2023-03-30 |
Family
ID=85721060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3232566A Pending CA3232566A1 (en) | 2021-09-22 | 2022-01-24 | Dried nanoparticle compositions |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12233160B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4404919A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024535351A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240088845A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022352486A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3232566A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023048758A1 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085881A1 (en) * | 2023-10-20 | 2025-04-24 | Eli Lilly And Company | Nanoparticles and formulations thereof for delivering therapeutic agents throughout the central nervous system |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024535352A (ja) * | 2021-09-22 | 2024-09-30 | エイチディーティー バイオ コーポレーション | Sars-cov-2 rnaワクチン組成物および使用方法 |
| GB202408358D0 (en) * | 2024-06-11 | 2024-07-24 | Uncommon Bio Ltd | Methods and compositions for transfecting cells |
| WO2026098357A1 (en) * | 2024-11-11 | 2026-05-15 | Kudo Biotechnology, Inc. | Freeze-dried nucleic acid-loaded lipid nanoparticle and reconstitution method thereof |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000050006A2 (en) | 1999-02-26 | 2000-08-31 | Chiron Corporation | Microemulsions with adsorbed macromoelecules and microparticles |
| WO2001021810A1 (en) | 1999-09-17 | 2001-03-29 | Aventis Pasteur Limited | Chlamydia antigens and corresponding dna fragments and uses thereof |
| AU2002305914A1 (en) | 2001-01-12 | 2002-10-21 | Chiron Corporation | Nucleic acid mucosal immunization |
| WO2003023026A1 (en) | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
| WO2004055216A2 (en) | 2002-12-13 | 2004-07-01 | Fox Chase Cancer Center | Replication of hepatitis c virus in non-hepatic epithelial and mouse hepatic cells |
| CA2539490A1 (en) | 2003-09-18 | 2005-03-24 | Genmab A/S | Differentially expressed tumour-specific polypeptides for use in the diagnosis and treatment of cancer |
| WO2005107760A1 (en) | 2004-04-30 | 2005-11-17 | Irm Llc | Compounds and compositions as inducers of keratinocyte differentiation |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| TWI388344B (zh) * | 2005-08-23 | 2013-03-11 | Celsion Corp | 儲存奈米微粒調合物之方法 |
| US9393215B2 (en) * | 2005-12-02 | 2016-07-19 | Novartis Ag | Nanoparticles for use in immunogenic compositions |
| EP2468300B1 (en) | 2006-09-26 | 2017-12-20 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| WO2008124647A2 (en) | 2007-04-04 | 2008-10-16 | Infectious Disease Research Institute | Immunogenic compositions comprising mycobacterium tuberculosis polypeptides and fusions thereof |
| US9446150B2 (en) | 2007-10-09 | 2016-09-20 | Washington University | Particles for imaging |
| US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
| AU2009280803B2 (en) * | 2008-07-23 | 2013-10-31 | Bharat Serums And Vaccines Ltd. | Stable injectable oil-in-water Docetaxel nanoemulsion |
| EP2401365B1 (en) | 2009-02-24 | 2016-04-27 | The Scripps Research Institute | Reengineering mrna primary structure for enhanced protein production |
| CA2764374C (en) | 2009-06-05 | 2019-11-19 | Infectious Disease Research Institute | Synthetic glucopyranosyl lipid adjuvants |
| CN102811743B (zh) * | 2009-12-11 | 2015-11-25 | 佰恩德治疗股份有限公司 | 冻干治疗颗粒的稳定制剂 |
| US8722853B2 (en) | 2010-06-10 | 2014-05-13 | University Of Washington Through Its Center For Commercialization | Methods and systems for adenovirus interaction with desmoglein 2 (DSG2) |
| US9555136B2 (en) | 2010-06-21 | 2017-01-31 | University Of Washington Through Its Center For Commercialization | Coated magnetic nanoparticles |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| US9655845B2 (en) | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| US9101669B2 (en) | 2012-01-31 | 2015-08-11 | Postech Academy-Industry Foundation | Self-assembed conjugate and use thereof |
| EP4299138A3 (en) | 2012-08-03 | 2024-08-14 | Access to Advanced Health Institute | Compositions and methods for treating an active mycobacterium tuberculosis infection |
| US20160000886A1 (en) | 2013-02-22 | 2016-01-07 | President And Fellows Of Harvard College | Nanostructured active therapeutic vehicles and uses thereof |
| US9775894B2 (en) | 2013-07-09 | 2017-10-03 | University Of Washington Through Its Center For Commercialization | Methods and compositions for activation of innate immune responses through RIG-I like receptor signaling |
| RU2546249C2 (ru) | 2013-08-07 | 2015-04-10 | Силезиа Груп Пте. Лтд. | Композиция для усиления экспрессии трансгена в эукариотических клетках и способ увеличения продукции целевого белка, кодируемого трансгеном |
| IL310015B2 (en) | 2013-12-31 | 2026-02-01 | Access To Advanced Health Inst | Single vial formulation |
| HRP20220070T1 (hr) | 2014-04-23 | 2022-04-01 | Modernatx, Inc. | Cjepiva nukleinske kiseline |
| SG11201705820UA (en) | 2015-01-16 | 2017-08-30 | Nat Inst Advanced Ind Science & Tech | Gene expression system using stealthy rna, and gene introduction/expression vector including said rna |
| AU2016251687C1 (en) | 2015-04-22 | 2023-07-27 | CureVac SE | RNA containing composition for treatment of tumor diseases |
| CN106176599A (zh) | 2015-05-06 | 2016-12-07 | 江苏天士力帝益药业有限公司 | 一种卡巴他赛脂肪乳注射剂及其制备方法 |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| KR20180082457A (ko) * | 2015-10-16 | 2018-07-18 | 마리누스 파마슈티컬스 인코포레이티드 | 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들 |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| DK3386484T3 (da) | 2015-12-10 | 2022-07-04 | Modernatx Inc | Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler |
| CN106880592B (zh) * | 2015-12-15 | 2021-04-06 | 江苏恒瑞医药股份有限公司 | 一种曲贝替定的纳米乳及其制备方法 |
| DE102017206254B4 (de) | 2016-04-13 | 2024-07-11 | Dialog Semiconductor (Uk) Limited | DC-DC-Umwandlung für Mehrzellen-Batterien |
| JP7250520B2 (ja) | 2016-04-13 | 2023-04-03 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 組換えアルテリウイルスレプリコン系およびその使用 |
| RU2761870C2 (ru) | 2016-05-16 | 2021-12-13 | Инфекшес Дизис Рисёрч Инститьют | Состав, содержащий агонист tlr, и способы применения |
| KR102483033B1 (ko) | 2016-05-16 | 2022-12-30 | 액세스 투 어드밴스드 헬스 인스티튜트 | 페길화된 리포솜 및 이의 용도 |
| EP3458088A2 (en) | 2016-05-21 | 2019-03-27 | Infectious Disease Research Institute | Compositions and methods for treating secondary tuberculosis and nontuberculous mycobacterium infections |
| EP3463300A1 (en) | 2016-06-01 | 2019-04-10 | Infectious Disease Research Institute | Nanoalum particles containing a sizing agent |
| EP3468537A1 (en) | 2016-06-14 | 2019-04-17 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018022957A1 (en) | 2016-07-29 | 2018-02-01 | Tarveda Therapeutics, Inc. | T cell binding conjugates and methods of use |
| KR20180025701A (ko) | 2016-09-01 | 2018-03-09 | (주)아모레퍼시픽 | 특정 siRNA을 포함하는 멜라닌 증진용 조성물 |
| WO2018053294A1 (en) | 2016-09-16 | 2018-03-22 | Infectious Disease Research Institute | Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy |
| ES2993107T3 (en) | 2016-10-17 | 2024-12-23 | Janssen Pharmaceuticals Inc | Recombinant virus replicon systems and uses thereof |
| WO2018081638A1 (en) | 2016-10-27 | 2018-05-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| WO2018147710A1 (ko) | 2017-02-13 | 2018-08-16 | 단디바이오사이언스 주식회사 | 이미다조퀴놀린계열 물질을 포함하는 나노에멀젼 및 이의 용도 |
| AU2018285694B2 (en) * | 2017-06-15 | 2025-04-10 | Access To Advanced Health Institute | Nanostructured lipid carriers and stable emulsions and uses thereof |
| US12065649B2 (en) | 2018-01-09 | 2024-08-20 | Vanderbilt University | Pattern recognition receptor agonist prodrugs and methods of use thereof |
| KR20200111729A (ko) | 2018-01-19 | 2020-09-29 | 얀센 파마슈티칼즈, 인코포레이티드 | 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진 |
| AU2019215191B2 (en) | 2018-02-02 | 2025-08-14 | University Of Washington | Compositions and methods for inducing tripartite motif-containing protein 16 (trim16) signaling |
| KR20210104835A (ko) | 2018-12-19 | 2021-08-25 | 누클레인, 엘엘씨 | 분자 진단을 위한 장치 및 방법 |
| WO2020146690A1 (en) | 2019-01-10 | 2020-07-16 | Massachusetts Institute Of Technology | Methods for in vitro evolution of rna replicons |
| US11406699B2 (en) | 2019-03-22 | 2022-08-09 | George Mason University | Alphavirus and compositions, methods, and kits related thereto |
| BR112021023726A2 (pt) | 2019-05-25 | 2022-02-15 | Infectious Disease Res Inst | Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante |
| GB201908729D0 (en) | 2019-06-18 | 2019-07-31 | Imp College Innovations Ltd | RNA construct |
| EP4004037A1 (en) | 2019-07-26 | 2022-06-01 | Vanderbilt University | Human monoclonal antibodies to enterovirus d68 |
| WO2021194672A1 (en) | 2020-03-23 | 2021-09-30 | Hdt Bio Corp. | Compositions and methods for delivery of rna |
| JP2022550454A (ja) | 2019-10-02 | 2022-12-01 | ユニバーシティ オブ ワシントン | B型肝炎ウイルス感染の治療のための組成物及び方法 |
| WO2021072112A1 (en) | 2019-10-09 | 2021-04-15 | Hdt Bio Corp. | Detection of desmoglein-2 in cancers of epithelial origin |
| AU2020367786A1 (en) | 2019-10-14 | 2022-05-26 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| BR112022016054A2 (pt) | 2020-02-14 | 2022-10-11 | Altimmune Inc | Composições imunogênicas para coronavírus e usos das mesmas |
| WO2021178416A1 (en) | 2020-03-02 | 2021-09-10 | Heat Biologics, Inc. | Immune-mediated coronavirus treatments |
| US11478543B1 (en) | 2020-03-06 | 2022-10-25 | Thomas Jefferson University | Coronavirus disease (COVID-19) vaccine |
| JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
| TWI891771B (zh) | 2020-04-17 | 2025-08-01 | 美商Vlp醫療股份有限公司 | 冠狀病毒疫苗 |
| US20230310323A1 (en) | 2020-09-04 | 2023-10-05 | Access To Advanced Health Institute | Co-lyophilized rna and nanostructured lipid carrier |
| JP2024501949A (ja) | 2020-12-23 | 2024-01-17 | アクセス ツー アドバンスト ヘルス インスティチュート | ソラネソールワクチンアジュバント及びその調製方法 |
| IN202121031414A (cg-RX-API-DMAC7.html) | 2021-07-13 | 2023-01-13 | ||
| IN202121038492A (cg-RX-API-DMAC7.html) | 2021-08-25 | 2023-03-03 | ||
| WO2023049636A2 (en) | 2021-09-22 | 2023-03-30 | Hdt Bio Corp. | Cancer therapy compositions and uses thereof |
| AU2022358446A1 (en) | 2021-09-22 | 2024-04-18 | Hdt Bio Corp. | Compositions and methods for enhanced protein production |
-
2022
- 2022-01-24 AU AU2022352486A patent/AU2022352486A1/en active Pending
- 2022-01-24 EP EP22873329.1A patent/EP4404919A4/en active Pending
- 2022-01-24 CA CA3232566A patent/CA3232566A1/en active Pending
- 2022-01-24 WO PCT/US2022/013508 patent/WO2023048758A1/en not_active Ceased
- 2022-01-24 KR KR1020247012267A patent/KR20240088845A/ko active Pending
- 2022-01-24 JP JP2024518361A patent/JP2024535351A/ja active Pending
-
2024
- 2024-03-19 US US18/609,128 patent/US12233160B2/en active Active
-
2025
- 2025-01-15 US US19/022,633 patent/US20250161214A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025085881A1 (en) * | 2023-10-20 | 2025-04-24 | Eli Lilly And Company | Nanoparticles and formulations thereof for delivering therapeutic agents throughout the central nervous system |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240088845A (ko) | 2024-06-20 |
| JP2024535351A (ja) | 2024-09-30 |
| US20250161214A1 (en) | 2025-05-22 |
| EP4404919A1 (en) | 2024-07-31 |
| EP4404919A4 (en) | 2025-08-20 |
| WO2023048758A1 (en) | 2023-03-30 |
| US20240216274A1 (en) | 2024-07-04 |
| US12233160B2 (en) | 2025-02-25 |
| AU2022352486A1 (en) | 2024-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12233160B2 (en) | Dried nanoparticle compositions | |
| US20230364260A1 (en) | Compositions and methods for delivery of rna | |
| US20250295751A1 (en) | Rna vaccines against infectious diseases | |
| EP3638207B1 (en) | Nanostructured lipid carriers and stable emulsions and uses thereof | |
| US20250228930A1 (en) | Sars-cov-2 rna vaccine compositions and methods of use | |
| US12485163B2 (en) | Cancer therapy compositions and uses thereof | |
| US20230310323A1 (en) | Co-lyophilized rna and nanostructured lipid carrier | |
| WO2025186725A2 (en) | Improved lnp formulations and uses thereof | |
| CN118284410A (zh) | 干燥的纳米颗粒组合物 | |
| WO2024089634A1 (en) | Immunogenic compositions against influenza and rsv | |
| CN118302154A (zh) | 抗感染性疾病rna疫苗 | |
| CN118555964A (zh) | 癌症治疗组合物及其用途 | |
| US20250152736A1 (en) | Immune system modulators and uses thereof | |
| CN118613491A (zh) | Sars-cov-2 rna疫苗组合物及使用方法 | |
| US20240269256A1 (en) | Compositions and methods for enhanced antigen binding proteins | |
| WO2025184356A1 (en) | Vaccines and compositions against gamma herpesviruses | |
| HK40108831A (zh) | 免疫原性lnp组合物及其方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241227 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241227 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241227 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251230 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251230 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260114 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260114 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260123 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260218 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260218 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260220 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260220 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260223 |